MAOLATE
LOE Approachingchlorphenesin carbamate
NDAORALTABLET
Approved
Jun 1965
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 16h ago · AI intelligence enriched 2mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MAOLATE (chlorphenesin carbamate) is an oral muscle relaxant tablet approved in 1965 as an NDA. The specific indications and mechanism of action are not documented in current data, typical of legacy products from this era.
LOE Approaching
Product approaching loss of exclusivity with minimal current commercial activity, signaling limited team expansion and defensive positioning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked jobs indicate minimal active hiring for MAOLATE roles. Working on this product offers stability in a legacy brand but limited career growth or cross-functional opportunities typical of expanding portfolios.
Brand ManagerField Sales Representative
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.